More than 400 comments were sent in regarding the American Society of Clinical Oncology (ASCO)'s Value Framework, and they will be incorporated as the framework evolves, explained Stephen Grubbs, MD, vice president for clinical affairs at ASCO.
More than 400 comments were sent in regarding the American Society of Clinical Oncology (ASCO)'s Value Framework, and they will be incorporated as the framework evolves, explained Stephen Grubbs, MD, vice president for clinical affairs at ASCO.
Transcript (slightly modified)
Are there plans to use feedback from the field to modify the ASCO Value Framework?
So the publication was done last year with the idea that people would comment upon that, and there’s been over 400 comments sent in to ASCO on this, and they are being taken into consideration and there are modifications of the tool. And beyond the comments, the tool needs to get more sophisticated in what it's measuring and I’ll give you an example.
Right now we’re measuring the net health benefit based on the advantage you get from the treatment but also the toxicities of the drugs. But we need to expand the negative part of that into how does it affect your family? How does it affect your quality of life? Can we get patient-reported outcomes involved in all this? So this is going to become very, very sophisticated, but at least the skeleton is there to build on right now.
This is not ready for primetime, but the conversation is going on, the modifications are being made, and we hope to see this evolve into an actually usable instrument where you might have a software program in your office where you can sit there with that patient. Of course, when you get to the cost part of it that’s different for every patient. It’s what payers are willing to pay for that and then what is their responsibility part of that so you have to adjust that per patient.
Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases
May 21st 2024Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Exploring Critical Advances in ARDS, Asthma, Lung Cancer, Health Equity at ATS 2024
May 20th 2024During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), childhood asthma, health equity, and lung cancer.
Read More